Impact Of Existing And Emerging Influenza A Viral Infections Drug Development Market Trends 2018

ResearchMoz presents professional and in-depth study of "Influenza A Viral Infections Drug Development Pipeline Review, 2018".

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1763912

Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

Scope

- Which companies are the most active within the pipeline for influenza A viral infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

View Complete TOC with tables & Figures @ https://www.researchmoz.us/influenza-a-viral-infections-drug-development-pipeline-review-2018-report.html/toc

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8

2 Introduction 10
2.1 Influenza A Viral Infections Report Coverage 10
2.2 Influenza A Virus, H3N2 Subtype Infections Overview 10
2.3 Influenza A Virus, H1N1 Subtype Infections Overview 10
2.4 Influenza A Virus, H5N1 Subtype Infections Overview 10
2.5 Influenza A Virus, H7N9 Subtype Infections Overview 10

3 Therapeutics Development 11
3.1 Influenza A Virus, H3N2 Subtype Infections 11
3.2 Influenza A Virus, H1N1 Subtype Infections 19
3.3 Influenza A Virus, H5N1 Subtype Infections 31
3.4 Influenza A Virus, H7N9 Subtype Infections 41

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1763912

4 Therapeutics Assessment 48
4.1 Influenza A Virus, H3N2 Subtype Infections 48
4.2 Influenza A Virus, H1N1 Subtype Infections 55
4.3 Influenza A Virus, H5N1 Subtype Infections 62
4.4 Influenza A Virus, H7N9 Subtype Infections 69

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/